EDN1 and diabetes mellitus: From this point of view, increased levels of sST2 in patients with diabetes and LVDD might be an epiphenomenon of other counteregulatory mechanisms such as endothelin 1 or to signify patients with failure of IL-33-induced cardioprotection, through sST2 acting as a decoy receptor.